Skip to content
Search

Latest Stories

SSPs reactivated for clarithromycin amid surging whooping cough cases

SSPs reactivated for clarithromycin amid surging whooping cough cases

The UK Health Security Agency (UKHSA) has confirmed 2,793 cases of whooping in the first quarter of 2024, including five infant deaths

As whooping cough cases rise sharply across the UK, the NHS has reactivated the serious shortage protocols (SSPs) for clarithromycin - a commonly prescribed antibiotic to treat this bacterial infection.


Pharmacy bodies had recently warned that community pharmacies were struggling to obtain source clarithromycin for patients.

Two SSPs, covering clarithromycin 125mg/5mL and 250mg/5mL oral suspensions, were reactivated on 22 May 2024, and extended until 21 June 2024.

These protocols state that for every 5mL of clarithromycin 125mg/5mL oral suspension, pharmacy contractors must supply 2.5mL of clarithromycin 250mg/5mL oral suspension; and for every 5mL of clarithromycin 250mg/5mL oral suspension, one clarithromycin 250mg tablet must be supplied.

The SSPs apply to cross-border prescriptions, both NHS and private.

Patients from England, Scotland, Wales or Northern Ireland who present their prescriptions for clarithromycin 125mg/5mL and 250mg/5mL oral suspensions are eligible to receive their substituted products under the terms of these SSPs.

If the pharmacist determines that the patient is unable to accommodate the switch from liquid to tablet (i.e. the patient cannot swallow tablets), they are advised to either contact the prescriber to discuss the issue (with the patient’s consent) or refer the patient back to the prescriber.

Can pharmacists supply an alternative product to patients? “If the pharmacist thinks that an alternative product, other than those listed within the SSP would be suitable for the patient, they should either contact the prescriber to discuss this (with the patient’s consent) or direct the patient back to the prescriber,” the NHS guidance said.

An SSP may be issued if the Department of Health and Social Care (DHSC) decides there is a serious shortage of a specific medicine or appliance.

When the SSPs for clarithromycin were first introduced in April 2023, they were originally intended to run for less than a month but were extended until December 2023.

The UK Health Security Agency (UKHSA) reported a total of 2,793 whooping cough cases in the first quarter of 2024 (January - March), comprising 556 cases in January, 918 in February, and 1,319 in March.

Sadly, there have been five infant deaths attributed to this lung-affecting bacterial infection this year so far.

More For You

Mike Hewitson, superintendent pharmacist & managing director of Beaminster Pharmacy

Mike Hewitson elected as NPA board member for England

Mike Hewitson elected as NPA board member for England: New term begins April

Mike Hewitson, superintendent pharmacist & managing director ofBeaminster Pharmacy, has been elected as the next National Pharmacy Association (NPA) board member for England.

Since 2023, Hewitson has served as chair of Community Pharmacy Dorset. He is also a member of Somerset Council and a Non-Executive Director at HubRx.

Keep ReadingShow less
Store closures 2024: Chemists among hardest hit

Over 600 chemist shops belonging to multiples and chains were closed last year

Getty Images

35 shops closed per day last year, chemists worst affected

More shops are expected to exit the UK high streets driven by driven by rising operational costs and a continued shift towards online shopping and transactions.

According to figures from PwC, a total of 12,804 outlets operated by chains (those with five or more locations) exited high streets, shopping centres and retail parks in 2024 – equivalent to 35 closures per day.

Keep ReadingShow less
Empty pharmacy shelves due to UK medicine shortages.

The government has said it's investing up to £520m to manufacture more medicines

Pic credit: iStock

Brexit blamed for UK medicine shortages with "little sign of recovery"

The UK is facing “a worsening situation” with drugs shortages compared to the rest of Europe as a result of Brexit, according to the Nuffield Trust health thinktank.

It comes of the back of data that revealed that the department of health and social care (DHSC) received 1,938 notifications of disruptions to medicine supply last year – the highest in four years.

Keep ReadingShow less
Alert! Patients on Promixin should be switched to alternatives by 30 April

Promixin is licensed for treating chronic pulmonary infections caused by Pseudomonas aeruginosa in adults and children with cystic fibrosis

Getty Images

Medicine shortage: Promixin to be discontinued from May 2025

The Department of Health and Social Care (DHSC) and NHS England have issued a national patient safety alert regarding the upcoming shortage of Promixin (colistimethate).

The alert, issued on 17 March 2025, states that Promixin (colistimethate) 1-million-unit powder for nebuliser solution unit dose vials (UDVs) will be discontinued from early May 2025, with stocks expected to be exhausted by this time.

Keep ReadingShow less
PAGB welcomes new vice-presidents and treasurer to Board

Rob Elliott and Bas Vorsteveld ( L-R)

Bas Vorsteveld will now oversee the Kenvue’s business in Northern Europe

PAGB appoints new vice-presidents and treasurer to Board

PAGB, the consumer healthcare association, has announced the appointment of two new vice-presidents and a treasurer to their Board.

Bas Vorsteveld, area managing director for Northern Europe at Kenvue, and Rob Elliott, OTC centre of excellence lead at Viatris, have been elected as vice-presidents.

Keep ReadingShow less